The Union Ministry of Health’s decision to lift the ban on methylcobalamin, a critical Vitamin B12 derivative, has yet to be formalized, leaving its regulatory status in limbo despite scientific backing and growing demand for its use in treating conditions such as diabetic neuropathy. While the Government of India’s Scientific Committee approved the molecule’s safety in 2019, the necessary gazette notification to officially lift the ban is still pending, raisin concerns among health professionals and industry stakeholders.
